Wedbush Securities Inc. boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 30.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,147 shares of the company’s stock after buying an additional 16,980 shares during the period. Wedbush Securities Inc.’s holdings in Teva Pharmaceutical Industries Limited were worth $2,397,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale raised its position in Teva Pharmaceutical Industries Limited by 7.2% in the second quarter. DekaBank Deutsche Girozentrale now owns 404,288 shares of the company’s stock worth $13,294,000 after buying an additional 27,094 shares during the period. First Trust Advisors LP raised its position in Teva Pharmaceutical Industries Limited by 10.5% in the second quarter. First Trust Advisors LP now owns 612,724 shares of the company’s stock worth $20,355,000 after buying an additional 58,414 shares during the period. Boston Partners raised its position in Teva Pharmaceutical Industries Limited by 32.6% in the second quarter. Boston Partners now owns 141,852 shares of the company’s stock worth $4,712,000 after buying an additional 34,846 shares during the period. Schwab Charles Investment Management Inc. raised its position in Teva Pharmaceutical Industries Limited by 7.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 241,571 shares of the company’s stock worth $8,025,000 after buying an additional 17,116 shares during the period. Finally, Wetherby Asset Management Inc. raised its position in Teva Pharmaceutical Industries Limited by 7.5% in the second quarter. Wetherby Asset Management Inc. now owns 9,374 shares of the company’s stock worth $311,000 after buying an additional 653 shares during the period. Institutional investors own 56.27% of the company’s stock.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 17.30 on Friday. Teva Pharmaceutical Industries Limited has a 1-year low of $16.81 and a 1-year high of $55.39. The stock’s 50 day moving average price is $29.64 and its 200 day moving average price is $31.56. The stock’s market capitalization is $17.58 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. The business had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business’s quarterly revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.25 earnings per share. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th will be given a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.97%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -18.95%.

COPYRIGHT VIOLATION WARNING: “Wedbush Securities Inc. Purchases 16,980 Shares of Teva Pharmaceutical Industries Limited (TEVA)” was originally posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/12/wedbush-securities-inc-purchases-16980-shares-of-teva-pharmaceutical-industries-limited-teva.html.

A number of research analysts have recently commented on TEVA shares. Zacks Investment Research downgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “strong sell” rating in a research note on Wednesday. Deutsche Bank AG reaffirmed a “buy” rating and set a $28.00 price objective (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday. Jefferies Group LLC reaffirmed a “hold” rating and set a $26.00 price objective (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price objective (down previously from $31.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $39.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday. Three research analysts have rated the stock with a sell rating, nineteen have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $37.69.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.